Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment

Int J Mol Sci. 2021 Oct 16;22(20):11161. doi: 10.3390/ijms222011161.

Abstract

The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine. Porphyrin-based, paddle-wheel framework (PPF) structures were obtained and tested as dual-kinetic Sorafenib (SOR) nanocarriers against hepatoma. We experimentally proved that sloughing of PPF structures combined with gradual dissolving are effective mechanisms for releasing the drug from the nanocarrier. By controlling the PPF degradation and size of adsorbed SOR deposits, we were able to augment SOR anticancer effects, both in vitro and in vivo, due to the dual kinetic behavior of SOR@PPF. Obtained drug delivery systems with slow and fast release of SOR influenced effectively, although in a different way, the cancer cells proliferation (reflected with EC50 and ERK 1/2 phosphorylation level). The in vivo studies proved that fast-released SOR@PPF reduces the tumor size considerably, while the slow-released SOR@PPF much better prevents from lymph nodes involvement and distant metastases.

Keywords: 2D metal–organic framework; PPF structure; anticancer drug delivery; multikinase inhibitors; sorafenib.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Biocompatible Materials / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Drug Delivery Systems / methods*
  • Drug Liberation
  • Humans
  • Liver Neoplasms / drug therapy*
  • MAP Kinase Signaling System
  • Metal-Organic Frameworks / therapeutic use*
  • Nanomedicine
  • Phosphorylation
  • Porphyrins / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Sorafenib / therapeutic use*

Substances

  • Antineoplastic Agents
  • Biocompatible Materials
  • Metal-Organic Frameworks
  • Porphyrins
  • Sorafenib